OBALON THERAPEUTICS INC·4

Nov 2, 2:24 PM ET

Rasdal Andrew P 4

4 · OBALON THERAPEUTICS INC · Filed Nov 2, 2017

Insider Transaction Report

Form 4
Period: 2017-10-31
Rasdal Andrew P
DirectorPresident & CEO
Transactions
  • Award

    Common Stock

    2017-10-31$7.17/sh+808$5,793454,071 total
Footnotes (1)
  • [F1]These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Documents

1 file
  • 4
    marketforms-40042.xmlPrimary

    PRIMARY DOCUMENT